Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine

CONTEXT: Recent studies support the hypothesis that postinfectious irritable bowel syndrome and some irritable bowel syndrome patients display persistent signs of minor mucosal inflammation. Mesalazine has intestinal anti-inflammatory properties including cyclooxygenase and prostaglandin inhibition. The effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome patients are still unknown. OBJECTIVE: To observe the effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with diarrhea patients. METHODS: Based on Rome III criteria, 61 irritable bowel syndrome with diarrhea patients (18 years old or more) were included in the evaluation. Patients were divided into two groups: postinfectious irritable bowel syndrome group, with 18 patients medicated with mesalazine 800 mg 3 times a day for 30 days; noninfective irritable bowel syndrome group, with 43 patients medicated with mesalazine 800 mg 3 times a day for 30 days. Symptom evaluations at baseline and after treatment were performed by means of a four-point Likert scale including stool frequency, stool form and consistency (Bristol Stool Scale), abdominal pain and distension (maximum score: 16; minimum score: 4). RESULTS: Postinfectious irritable bowel syndrome group presented a statistically significant reduction of the total symptom score (P<0.0001). The stool frequency was significantly reduced (P<0.0001), and stool consistency, improved (P<0.0001). Abdominal pain (P<0.0001) and abdominal distension were significantly reduced (P<0.0001). Noninfective irritable bowel syndrome group presented a statistically significant reduction of total symptom score (P<0.0001). Also, the stool frequency was significantly reduced (P<0.0001) and stool consistency, improved (P<0.0001). Abdominal pain (P<0.0001) and abdominal distention were significantly reduced (P<0.0001). There was no statistical difference between postinfectious irritable bowel syndrome group and noninfective irritable bowel syndrome group on total symptom score results at 30th day of therapy with mesalazine 800 mg 3 times a day. (P = 0.13). CONCLUSION: Mesalazine reduced key symptoms of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with diarrhea patients.

Coping styles and defense mechanisms utilised by patients suffering from irritable bowel syndrome

The goal of the research was to determine whether people suffering from lrritable Bowel Syndrome (IBS), differ from non-Irritable Bowel Syndrome sufferers in terms of their coping styles and defense mechanisms. The research project was divided into two studies, namely: the first studied coping styles used by lrritable Bowel Syndrome sufferers and the second study focused on the defense mechanisms of the same group. The sample consisted of 30 white women between the ages of 25 and 55 years, diagnosed with lrritable Bowel Syndrome. A control group, consisting of 30 same-aged white women was also studied studied. The results show a significant difference between the lrritable Bowel Syndrome group and the non-Irritable Bowel Syndrome group as measured by the Ways of Coping Questionnaire (WCQ), the Defense Mechanisms lnventory (DMI) and the Coping perations Preference Enquiry (COPE). The implicati&s of these studies may be of great value in the non-pharmacological management or control of lrritable Bowel Syndrome. Possible directions for future research are proposed.OpsommingDie doel van die navorsing was om vas te stel of mense wat aan Prikkelbare Dermsindroom (PDS) ly, verskil van nie-Prikkelbare Dermsindroom lyers in terme van hulle hanteringsmeganismes en verdedigingsmeganismes. Die navorsing is in twee studies verdeel, naamlik: die eerste het hanteringstyle bestudeer wat gebruik word deur persone wat aan Prikkelbare Dermsindroom ly en die tweede studie het die verdedigingsmeganismes bestudeer in dieselfde groep. Die steekproef het bestaan uit 30 wit vrouens tussen die ouderdomme van 25 en 55 jaar wat gediagnoseer is met Prikkelbare Dermsindroom. 'n Kontrolegroep, bestaande uit 30 wit vrouens in dieselfde ouderdomsgroep, is ook bestudeer. Die resultate dui op 'n statisties beduidende verskil tussen die Prikkelbare Dermsindroom groep en die nie-Prikkelbare Dermsindroom groep soos gemeet deur die "Ways of Coping Questionnaire", die "Defense Mechanisms lnventory (DMI)" en die "Coping Operations Preference Enquiry (COPE)". Die implikasie van die studies mag van groot waarde wees in die nie-farmakologiese bestuur of beheer van Prikkelbare Dermsindroom. Moontlike rigtings vir toekomstige navorsing word voorgestel.